{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:19:48Z","timestamp":1794647988142,"version":"4.9.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Actelion Pharmaceuticals Nederland"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>SSc is a chronic autoimmune disease characterized by microvascular injury and impaired angiogenesis, with endothelial progenitor cells (EPCs) playing a key role in vascular repair. EPC subsets, including endothelial colony-forming cells (ECFCs) and colony-forming unit-endothelial cells (CFU-ECs), are known to be dysfunctional in SSc, contributing to disease-associated vasculopathy. Prostaglandin E1 (PGE1) is a vasodilator with potential pro-angiogenic effects, but its impact on EPC numbers and function in SSc remains unexplored. This study aimed to investigate whether PGE1 treatment can modulate EPC numbers, specifically CFU-ECs and ECFCs, in patients with SSc and RP, and evaluate its potential role in promoting vascular repair.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study evaluated the effect of PGE1 on EPC levels in 12 SSc patients with RP and five healthy controls (HCs). CFU-EC and ECFC clusters were quantified before and after PGE1 treatment using standardized culture methods. PGE1 was administered intravenously over 8\u20139\u2009days. Statistical analyses compared EPC counts between the groups and time points.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Baseline CFU-EC and ECFC cluster counts were significantly reduced in SSc patients compared with HCs (P\u2009=\u20090.02 and P\u2009&amp;lt;\u20090.01, respectively). Following PGE1 treatment, both CFU-EC and ECFC clusters significantly increased in SSc patients (P\u2009=\u20090.02 and P\u2009=\u20090.001, respectively), reaching levels comparable to HCs. No significant changes were observed in HCs across two time points. A significant delta in cluster counts was observed in SSc patients vs. HCs (CFU-EC: P\u2009=\u20090.03; ECFC: P\u2009=\u20090.01).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>PGE1 treatment restores CFU-EC and ECFC levels in SSc patients, suggesting a potential role in repairing vascular damage. These findings highlight PGE1\u2019s therapeutic benefits beyond vasodilation, supporting its use in SSc-associated microvasculopathy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf174","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T23:56:12Z","timestamp":1743206172000},"page":"4761-4765","source":"Crossref","is-referenced-by-count":6,"title":["Prostaglandin E1 restores endothelial progenitor cell function in systemic sclerosis"],"prefix":"10.1093","volume":"64","author":[{"given":"Judith","family":"Potjewijd","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Clinical & Experimental Immunology, CARIM, Maastricht University Medical Center , Maastricht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Tobal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Clinical & Experimental Immunology, CARIM, Maastricht University Medical Center , Maastricht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J","family":"Arends","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Clinical & Experimental Immunology, CARIM, Maastricht University Medical Center , Maastricht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucienne","family":"Debrus-Palmans","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Clinical & Experimental Immunology, CARIM, Maastricht University Medical Center , Maastricht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4007-6985","authenticated-orcid":false,"given":"Jan G M C","family":"Damoiseaux","sequence":"additional","affiliation":[{"name":"Central Diagnostic Laboratory, Maastricht University Medical Center , Maastricht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"van Paassen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Clinical & Experimental Immunology, CARIM, Maastricht University Medical Center , Maastricht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"2025080115372937000_keaf174-B1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"2025080115372937000_keaf174-B2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41584-020-0386-4","article-title":"Raynaud phenomenon and digital ulcers in systemic sclerosis","volume":"16","author":"Hughes","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2025080115372937000_keaf174-B3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5301\/jsrd.5000249","article-title":"Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities","volume":"2","author":"Varga","year":"2017","journal-title":"J Scleroderma Relat"},{"key":"2025080115372937000_keaf174-B4","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3389\/fimmu.2018.01383","article-title":"The role of endothelial progenitors in the repair of vascular damage in systemic sclerosis","volume":"9","author":"Del Papa","year":"2018","journal-title":"Front Immunol"},{"key":"2025080115372937000_keaf174-B5","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1126\/science.275.5302.964","article-title":"Isolation of putative progenitor endothelial cells for angiogenesis","volume":"275","author":"Asahara","year":"1997","journal-title":"Science"},{"key":"2025080115372937000_keaf174-B6","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1056\/NEJMoa022287","article-title":"Circulating endothelial progenitor cells, vascular function, and cardiovascular risk","volume":"348","author":"Hill","year":"2003","journal-title":"N Engl J Med"},{"key":"2025080115372937000_keaf174-B7","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1161\/STROKEAHA.107.507251","article-title":"Endothelial progenitor cell research in stroke. A potential shift in pathophysiological and therapeutical concepts","volume":"39","author":"Rouhl","year":"2008","journal-title":"Stroke"},{"key":"2025080115372937000_keaf174-B8","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.5152\/eurjrheum.2019.19158","article-title":"Endothelial cells and endothelial progenitor cells in the pathogenesis of systemic sclerosis","volume":"7","author":"Ota","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"2025080115372937000_keaf174-B9","first-page":"1","article-title":"Human endothelial colony-forming cells","volume":"12","author":"Melero-Martin","year":"2022","journal-title":"CSH Perspect Med"},{"key":"2025080115372937000_keaf174-B10","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/sctm.16-0360","article-title":"Endothelial progenitors: a consensus statement on nomenclature","volume":"6","author":"Medina","year":"2017","journal-title":"Stem Cells Transl Med"},{"key":"2025080115372937000_keaf174-B11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"Del Galdo","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2025080115372937000_keaf174-B12","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.yjmcc.2006.12.017","article-title":"Regulation of endothelial progenitor cells by prostaglandin E1 via inhibition of apoptosis","volume":"42","author":"Gensch","year":"2007","journal-title":"J Mol Cell Cardiol"},{"key":"2025080115372937000_keaf174-B13","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025080115372937000_keaf174-B14","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J Rheumatol"},{"key":"2025080115372937000_keaf174-B15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2174\/156720209787466082","article-title":"Haptoglobin phenotype may alter endothelial progenitor cell cluster formation in cerebral small vessel disease","volume":"6","author":"Rouhl","year":"2009","journal-title":"Curr Neurovasc Res"},{"key":"2025080115372937000_keaf174-B16","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa043814","article-title":"Circulating endothelial progenitor cells and cardiovascular outcomes","volume":"353","author":"Werner","year":"2005","journal-title":"N Engl J Med"},{"key":"2025080115372937000_keaf174-B17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13075-016-1044-8","article-title":"Endothelial progenitor cells are differentially impaired in ANCA-associated vasculitis compared to healthy controls","volume":"18","author":"Wilde","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2025080115372937000_keaf174-B18","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0140-6736(04)16853-0","article-title":"Defective vasculogenesis in systemic sclerosis","volume":"364","author":"Kuwana","year":"2004","journal-title":"Lancet"},{"key":"2025080115372937000_keaf174-B19","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/art.20116","article-title":"Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis","volume":"50","author":"Del Papa","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2025080115372937000_keaf174-B20","first-page":"60","article-title":"Levels of circulating endothelial progenitor cells in systemic sclerosis","volume":"25","author":"Allanore","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"2025080115372937000_keaf174-B21","doi-asserted-by":"crossref","first-page":"14385","DOI":"10.3390\/ijms241814385","article-title":"Endothelial dysfunction in systemic sclerosis","volume":"24","author":"Patnaik","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025080115372937000_keaf174-B22","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1002\/art.22035","article-title":"Bone marrow endothelial progenitors are defective in systemic sclerosis","volume":"54","author":"Del Papa","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2025080115372937000_keaf174-B23","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/annrheumdis-2011-200713","article-title":"Quantification of circulating endothelial progenitor cells in systemic sclerosis: a direct comparison of protocols","volume":"71","author":"Kuwana","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2025080115372937000_keaf174-B24","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2006-08-043471","article-title":"Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem\/progenitor cell principals","volume":"109","author":"Yoder","year":"2007","journal-title":"Blood"},{"key":"2025080115372937000_keaf174-B25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1538-7836.2009.03407.x","article-title":"Defining human endothelial progenitor cells","volume":"7","author":"Yoder","year":"2009","journal-title":"J Thromb Haemost"},{"key":"2025080115372937000_keaf174-B26","first-page":"358","article-title":"Prostaglandin E1 restores the levels of vWF and ACE in chronic critical limb ischemia in systemic sclerosis","volume":"19","author":"Pignone","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"2025080115372937000_keaf174-B27","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12931-023-02559-3","article-title":"Prostaglandin and prostaglandin receptors: present and future promising therapeutic targets for pulmonary arterial hypertension","volume":"24","author":"Zeng","year":"2023","journal-title":"Respir Res"},{"key":"2025080115372937000_keaf174-B28","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cvr\/cvm085","article-title":"Protein kinase C alpha promotes angiogenic activity of human endothelial cells via induction of vascular endothelial growth factor","volume":"78","author":"Xu","year":"2008","journal-title":"Cardiovasc Res"},{"key":"2025080115372937000_keaf174-B29","doi-asserted-by":"crossref","first-page":"1602493","DOI":"10.1183\/13993003.02493-2016","article-title":"Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension","volume":"50","author":"Gaine","year":"2017","journal-title":"Eur Respir J"},{"key":"2025080115372937000_keaf174-B30","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1164\/rccm.201908-1640OC","article-title":"Combination therapy with oral treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial","volume":"201","author":"White","year":"2020","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf174\/62703392\/keaf174.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/8\/4761\/62703392\/keaf174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/8\/4761\/62703392\/keaf174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T19:37:36Z","timestamp":1754077056000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/8\/4761\/8093285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,3,25]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf174","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,3,25]]}}}